[go: up one dir, main page]

CA2410419A1 - Procede ameliore de transfection - Google Patents

Procede ameliore de transfection Download PDF

Info

Publication number
CA2410419A1
CA2410419A1 CA002410419A CA2410419A CA2410419A1 CA 2410419 A1 CA2410419 A1 CA 2410419A1 CA 002410419 A CA002410419 A CA 002410419A CA 2410419 A CA2410419 A CA 2410419A CA 2410419 A1 CA2410419 A1 CA 2410419A1
Authority
CA
Canada
Prior art keywords
cells
cell
transfection
nucleic acid
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002410419A
Other languages
English (en)
Inventor
Stephen Lewis Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICH Productions Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0013090A external-priority patent/GB0013090D0/en
Priority claimed from GB0013089A external-priority patent/GB0013089D0/en
Application filed by Individual filed Critical Individual
Publication of CA2410419A1 publication Critical patent/CA2410419A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne la transfection de cellules confluentes ou autres cellules à division lente ou sans division, en contact mutuel, par le biais d'un acide nucléique dépourvu de vecteur ciblé sur récepteur non viral, sachant que cette transfection peut être améliorée par l'utilisation concurrente d'un agent qui défait les liens entre cellules, en particulier l'EGTA. En particulier, le vecteur est un complexe à vecteur de transfection ciblant l'intégrine qui comprend (i) un acide nucléique, notamment un acide nucléique codant une séquence visée, (ii) un composant de liaison avec l'intégrine, notamment un peptide ciblant l'intégrine, (iii) un composant de liaison avec un acide nucléique polycationique, notamment une oligosine, et (iv) un composant lipide, notamment DOPE, DOTMA, DOSPA ou des combinaisons de ces éléments. L'invention concerne par ailleurs diverses applications du procédé de transfection amélioré qui est décrit.
CA002410419A 2000-05-30 2001-05-30 Procede ameliore de transfection Abandoned CA2410419A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0013090A GB0013090D0 (en) 2000-05-30 2000-05-30 Intergrin-targetting vectors having enhanced transfection activity
GB0013090.6 2000-05-30
GB0013089A GB0013089D0 (en) 2000-05-30 2000-05-30 Improved methods of transfection
GB0013089.8 2000-05-30
US28741001P 2001-05-01 2001-05-01
US60/287,410 2001-05-01
PCT/GB2001/002396 WO2001092543A2 (fr) 2000-05-30 2001-05-30 Procede ameliore de transfection

Publications (1)

Publication Number Publication Date
CA2410419A1 true CA2410419A1 (fr) 2001-12-06

Family

ID=27255741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002410419A Abandoned CA2410419A1 (fr) 2000-05-30 2001-05-30 Procede ameliore de transfection

Country Status (5)

Country Link
EP (1) EP1285081A2 (fr)
JP (1) JP2003534804A (fr)
AU (2) AU2001260467A1 (fr)
CA (1) CA2410419A1 (fr)
WO (2) WO2001092543A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268668B2 (en) 2003-05-09 2007-09-11 American Express Travel Related Services Company, Inc. Systems and methods for managing multiple accounts on a RF transaction instrument
US7514098B2 (en) * 2001-05-30 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Use of targeted cross-linked nanoparticles for in vivo gene delivery
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
FR2860236B1 (fr) * 2003-09-25 2006-01-06 Theraptosis Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique
AU2009206212B2 (en) 2008-01-24 2014-01-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
EP3468613A1 (fr) 2016-06-09 2019-04-17 CureVac AG Supports hybrides pour cargo d'acides nucléiques
US20190336608A1 (en) * 2016-06-09 2019-11-07 Curevac Ag Cationic carriers for nucleic acid delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067183A1 (fr) * 1989-09-27 1991-03-28 Lee L. Rubin Composition pour l'inhibition de l'adhesion cellulaire et methode d'utilisation
CA2131620A1 (fr) * 1992-03-20 1993-09-30 Louis C. Smith Systeme de transport de l'adn et mode d'emploi
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6252045B1 (en) * 1996-03-15 2001-06-26 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
WO1999018792A1 (fr) * 1997-10-10 1999-04-22 Johns Hopkins University Compositions et procedes d'apport de genes
AU2662999A (en) * 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
US6448390B1 (en) * 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
WO2000062815A2 (fr) * 1999-04-15 2000-10-26 Glaxo Group Limited Nouvelle composition pharmaceutique utilisable en therapie genique

Also Published As

Publication number Publication date
WO2001092543A2 (fr) 2001-12-06
WO2001092542A3 (fr) 2003-05-30
JP2003534804A (ja) 2003-11-25
WO2001092542A2 (fr) 2001-12-06
WO2001092542A8 (fr) 2003-12-24
WO2001092543A3 (fr) 2002-09-12
AU2001260467A1 (en) 2001-12-11
AU2001258659A1 (en) 2001-12-11
EP1285081A2 (fr) 2003-02-26

Similar Documents

Publication Publication Date Title
EP1003898B1 (fr) Vecteurs de ciblage d'integrine presentant une activite de transfection
Hart et al. Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector
Perales et al. An evaluation of receptor‐mediated gene transfer using synthetic DNA‐ligand complexes
Mahato Non-viral peptide-based approaches to gene delivery
Davis et al. Vectors for airway gene delivery
US8026341B2 (en) Transfection complexes
Kabanov et al. Efficient transformation of mammalian cells using DNA interpolyelectrolyte complexes with carbon chain polycations
US6372720B1 (en) Liposome fusion and delivery vehicle
Welser et al. Gene delivery using ternary lipopolyplexes incorporating branched cationic peptides: the role of peptide sequence and branching
US20030162293A1 (en) Cell transfection compositions comprising genetic material, an amphipathic compound and an enzyme inhibitor and method of use
US6927278B1 (en) Peptide scaffolds for transfer of molecules into eukaryotic cells
CA2410419A1 (fr) Procede ameliore de transfection
KR20010114237A (ko) 에어로졸 전달용 폴리에틸렌이민:ｄｎａ 제형
US20040014217A1 (en) Methods of transfection
EP1007549B1 (fr) Compositions et procedes pour une transfection tres efficace
Wagner Functional polymer conjugates for medicinal nucleic acid delivery
Norton et al. Methods for DNA introduction into mammalian cells
WO2000012114A1 (fr) Structures peptidiques permettant de transferer des molecules dans des cellules eukariotes
Jordan Synthetic and semisynthetic polymers as vehicles for in vitro gene delivery into cultured mammalian cells
Merdan Polyethylenimine and its derivates: investigation of in vivo fate, subcellular trafficking and development of novel vector systems
Hart et al. Integrin-Mediated Gene Delivery
Chow In vitro studies of cationic liposome mediated gene delivery
Jordan Synthetic and Semisynthetic Polymers as Vehicles for In Vitro Gene Delivery
Smith et al. DNA DELIVERY SYSTEMS BASED ON SYNTHETIC PEPTIDES
Nwachuku An investigation of peptide-based translocating systems and their potential for gene therapy

Legal Events

Date Code Title Description
FZDE Dead